Condition: Intensive Care Unit · Coronary Artery Bypass Grafting (CABG) · High Risk Patients · Sponsor: GCP-Service International West GmbH
The MODIFY CSX study is a prospective, randomized, placebo-controlled trial conducted in heart centers in Germany and Italy. A total of 550 high-risk cardiac surgery patients will receive either 0.20 g fish oil/kg body weight (BW) + standard of care versus same volume of placebo (NaCl) + standard of care.
This description comes directly from the study's public registry record.
Christian Stoppe, Prof. Dr. · 49-931-20130001 · cstoppe@gcp-service.com
Ellen Dresen, Dr. · +49 931-201 30392 · Dresen_E@ukw.de
Always discuss trial participation with your own doctor first.
| University Hospital Augsburg | Augsburg, Germany | Recruiting |
| Charité Universitätsmedizin Berlin | Berlin, Germany | Recruiting |
| University of Bonn | Bonn, Germany | Recruiting |
| University Hospital Goettingen | Göttingen, Germany | Recruiting |
| University Hospital Hamburg-Eppendorf | Hamburg, Germany | Recruiting |
| University Medical Center Schleswig-Holstein | Kiel, Germany | Recruiting |
| University Hospital Mainz | Mainz, Germany | Recruiting |
| University Hospital Muenster | Münster, Germany | Recruiting |
| University Medical Center Rostock | Rostock, Germany | Not Yet Recruiting |
| Robert Bosch Medical Center | Stuttgart, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06279793